114 related articles for article (PubMed ID: 8853970)
1. Costs and benefits of cervical screening. II. Is it worthwhile reducing the screening interval from 5 to 3 years?
Waugh N; Robertson A
Cytopathology; 1996 Aug; 7(4):241-8. PubMed ID: 8853970
[TBL] [Abstract][Full Text] [Related]
2. Costs and benefits of cervical screening. III. Cost/benefit analysis of a call of previously unscreened women.
Waugh N; Smith I; Robertson A; Reid GS; Halkerston R; Grant A
Cytopathology; 1996 Aug; 7(4):249-55. PubMed ID: 8853971
[TBL] [Abstract][Full Text] [Related]
3. Costs and benefits of cervical screening. I. The costs of the cervical screening programme.
Waugh N; Smith I; Robertson A; Reid GS; Halkerston R; Grant A
Cytopathology; 1996 Aug; 7(4):231-40. PubMed ID: 8853969
[TBL] [Abstract][Full Text] [Related]
4. Does cervical cancer screening do more harm than good?
Payne L; Lavis P
Nurs Times; 2001 Jul 19-25; 97(29):20. PubMed ID: 11957496
[No Abstract] [Full Text] [Related]
5. Evaluation of cervical cytology.
McCrory DC; Matchar DB; Bastian L; Datta S; Hasselblad V; Hickey J; Myers E; Nanda K
Evid Rep Technol Assess (Summ); 1999 Jan; (5):1-6. PubMed ID: 11925972
[No Abstract] [Full Text] [Related]
6. Liquid-based cytology in cervical screening: a rapid and systematic review.
Payne N; Chilcott J; McGoogan E
Health Technol Assess; 2000; 4(18):1-73. PubMed ID: 10932023
[No Abstract] [Full Text] [Related]
7. Is cervical screening necessary in older women?
Cruickshank ME
Cytopathology; 2001 Dec; 12(6):351-3. PubMed ID: 11843936
[No Abstract] [Full Text] [Related]
8. Costs and benefits of cervical screening IV: valuation by women of the cervical screening programme.
Wordsworth S; Ryan M; Waugh N
Cytopathology; 2001 Dec; 12(6):367-76. PubMed ID: 11843938
[TBL] [Abstract][Full Text] [Related]
9. Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening.
Myers ER; McCrory DC; Subramanian S; McCall N; Nanda K; Datta S; Matchar DB
Obstet Gynecol; 2000 Nov; 96(5 Pt 1):645-52. PubMed ID: 11042294
[TBL] [Abstract][Full Text] [Related]
10. [A reply on cervix cancer screening: cervical cytological test doesn't fulfil the requirements of a good screening test].
Bistoletti P
Lakartidningen; 2000 Sep; 97(37):4042. PubMed ID: 11036367
[No Abstract] [Full Text] [Related]
11. In vitro conventional cytology historical strengths and current limitations.
Spitzer M
Obstet Gynecol Clin North Am; 2002 Dec; 29(4):673-83. PubMed ID: 12509091
[TBL] [Abstract][Full Text] [Related]
12. Economic aspects of screening for cervical cancer in New Zealand.
Bethwaite J; Rayner T; Bethwaite P
N Z Med J; 1986 Oct; 99(811):747-51. PubMed ID: 3464889
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
Kim JJ; Leung GM; Woo PP; Goldie SJ
J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
[TBL] [Abstract][Full Text] [Related]
14. Cost-effective policies for cervical cancer screening. An international review.
Fahs MC; Plichta SB; Mandelblatt JS
Pharmacoeconomics; 1996 Mar; 9(3):211-30. PubMed ID: 10160098
[TBL] [Abstract][Full Text] [Related]
15. Managing incidents in the cervical screening programme.
Wilkinson MJ
Cytopathology; 2000 Oct; 11(5):287-9. PubMed ID: 11014655
[No Abstract] [Full Text] [Related]
16. Does the increased sensitivity of the new Papanicolaou (Pap) tests improve the cost-effectiveness of screening for cervical cancer?
Reust CE
J Fam Pract; 2001 Feb; 50(2):175. PubMed ID: 11219567
[No Abstract] [Full Text] [Related]
17. Cervical screening interval: costing the options in one health authority.
Grant CM
J Public Health Med; 1999 Jun; 21(2):140-4. PubMed ID: 10432241
[TBL] [Abstract][Full Text] [Related]
18. [Costs and problems in cervix cancer screening are considerably underestimated].
Bistoletti P
Lakartidningen; 2000 Aug; 97(32-33):3506-8. PubMed ID: 11037597
[No Abstract] [Full Text] [Related]
19. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia.
Perovic S
J BUON; 2009; 14(1):93-6. PubMed ID: 19373953
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors.
Taylor LA; Sorensen SV; Ray NF; Halpern MT; Harper DM
Arch Fam Med; 2000 Aug; 9(8):713-21. PubMed ID: 10927709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
